Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SAT1 | P21673 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097547 | 1.00 | KDM1A (0.79) | KDM1ACYP2C19CYP1A2MEN1GLA | |
| SCHEMBL12951513 | 0.89 | KDM1A (1.00) | KDM1ACYP2C19CYP1A2MEN1GLA | |
| SCHEMBL14876581 | 0.89 | KDM1A (1.00) | KDM1ACYP2C19CYP1A2MEN1GLA | |
| SCHEMBL14876580 | 0.89 | KDM1A (1.00) | KDM1ACYP2C19CYP1A2MEN1GLA | |
| SCHEMBL12951514 | 0.87 | KDM1A (0.95) | KDM1ACYP2C19CYP1A2MEN1GLA | |
| SCHEMBL12951422 | 0.87 | KDM1A (0.95) | KDM1ACYP2C19CYP1A2MEN1GLA | |
| SCHEMBL13097481 | 0.87 | KDM1A (0.95) | KDM1ACYP2C19CYP1A2MEN1GLA | |
| SCHEMBL12085577 | 0.87 | KDM1A (0.95) | KDM1ACYP2C19CYP1A2MEN1GLA | |
| SCHEMBL12951475 | 0.87 | CYP2C19 (0.68) | KDM1ACYP2C19CYP1A2MEN1GLA | |
| SCHEMBL14377823 | 0.85 | KDM1A (0.75) | KDM1ACYP2C19CYP1A2MEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653238-B2 | Compositions and methods for transport of molecules with enhanced release properties across biological barriers | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-20100255499-A1 | COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-07 | — | — | US | disclosed |
| US-20090143456-A1 | Polyamine Analogs as Modulators of Cell Migration and Cell Motility | PROGEN PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | CELLGATE, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186825-B2 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | SRM, SMS, PCNA | KDM1A 777/4885CYP2C19 4775/4885CYP1A2 4812/4885 |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | KDM1A 546/4885CYP2C19 3757/4885CYP1A2 4456/4885 |
| US-20090143456-A1 | Polyamine Analogs as Modulators of Cell Migration and Cell Motility | SRM, MIF, PTGIS | KDM1A 3167/4885CYP2C19 4180/4885CYP1A2 4612/4885 |
| US-20100255499-A1 | COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS | SLC2A9, SLC43A1, SLC2A8 | KDM1A 4561/4885CYP2C19 4027/4885CYP1A2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.